Physician profile
Errol Wilder
NPI 1790815512
$3,267.47
in general payments reported to CMS, 2019-2025
34 companies · $752 in 2025
The $752 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $40.67 · 2021: $317 · 2022: $603 · 2023: $738 · 2024: $585 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $411.12 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $404.75 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $400.72 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $382.62 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $257.94 | 2020-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $135.96 | 2025 | Gemtesa |
| Pfizer INC. | $120.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.24 | 2021-2022 | |
| Amgen INC. | $98.56 | 2021-2025 | Otezla, Repatha, Repatha |
| Noven Therapeutics, LLC | $95.17 | 2023 | Xelstrym, Secuado |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.52 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $85.51 | 2022-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $75.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Supernus Pharmaceuticals, INC. | $66.68 | 2023-2024 | Qelbree, Qelbree |
| Phathom Pharmaceuticals, INC. | $52.70 | 2023-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.73 | 2024 | Rexulti |
| Antares Pharma, INC. | $42.08 | 2019-2023 | Tlando, Nocdurna, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $37.63 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $34.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.50 | 2022 | |
| Biocryst US Sales Co., LLC | $30.13 | 2024 | Orladeyo |
| Dexcom, INC. | $30.04 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.66 | 2025 | Caplyta |
| Abbvie INC. | $23.66 | 2024 | |
| Corium, LLC | $20.02 | 2024 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $19.96 | 2022 | |
| Saluda Medical Americas, INC. | $19.33 | 2024 | Evoke |
| Shield Therapeutics INC | $17.88 | 2024 | |
| Gilead Sciences, INC. | $17.74 | 2023 | |
| Amarin Pharma, INC. | $17.37 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.71 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.56 | 2022 | |
| Tris Pharma INC | $16.48 | 2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $14.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Errol Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.